| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7fe79f6eb1e709dbf956eaeaccc1c540 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57423
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57449
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57488
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-82 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2011-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2016-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_890f9ab63548b2943eac281aa0aa7e1b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1f824bbb92294e7b9a47e766281d4b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2f82267d44d4e9717a56698743656d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b79f8f08c39cac6e83136aff6180f8a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_440ae482fdbdf11f834918e151585f9a |
| publicationDate |
2016-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2011323124-C1 |
| titleOfInvention |
Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
| abstract |
The present invention provides methods and kits for assessing whether a subject is afflicted with an FRα-expressing cancer, methods and kits for predicting the progression of ovarian cancer in a subject afflicted with an FRα-expressing cancer, methods and kits for assessing the level of risk that a subject will develop an FRα- expressing cancer, and methods of stratifying a subject with an FRα-expressing cancer into cancer therapy groups. The methods involve determining the level of folate receptor alpha (FRα) which is not bound to a cell in a sample derived from the subject and comparing this level with the level of FRα in a control sample. |
| priorityDate |
2010-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |